Bile Duct Cancer Enters Targeted Therapy Era As Agios And Incyte Prepare Filings
Results from two studies at ESMO point to a targeted future for cholangiocarinoma with Agios and Incyte both planning year-end FDA filings in different patient subsets.
You may also be interested in...
Biotech hopes this initial approval will be followed by approvals of Pemazyre in bladder cancer, first-line cholangiocarcinoma and possibly even a tumor-agnostic indication for FGFR-mutated cancers.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
The latest drug development news and highlights from our US FDA Performance Tracker.